Healio
Healio
21003793_EF156_THin_MM_collection_banner

Take Homes in Multiple Myeloma
ByAdam D. Cohen, MD
ByGeorgia I Salvaryn
Fact checked byMindy Valcarcel, MS

Read more

June 24, 2024
4 min watch
Save

VIDEO: Isatuximab-VRd more effective in treating older patients with multiple myeloma

ByAdam D. Cohen, MD
ByGeorgia I Salvaryn
Fact checked byMindy Valcarcel, MS

CHICAGO — In this video, Adam Cohen, MD, spoke to Healio about the role of quadruplet induction regimens for transplant-ineligible patients with multiple myeloma.

IMROZ and BENEFIT, randomized phase 3 trials presented at ASCO Annual Meeting, investigated the combination of isatuximab (Sarclisa, Sanofi) with bortezomib, lenalidomide and dexamethasone (VRd) as a treatment for newly diagnosed older patients. Both trials proved isatuximab-VRd was more effective than the first-line treatment option.

“[This is] additional evidence suggesting maybe we should start thinking about quadruplets even for our older patients,” Cohen, associate professor of medicine in hematology-oncology at Hospital of the University of Pennsylvania, said.

References:

  • Facon T, et al. Abstract 7500. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
  • Leleu XP, et al. Abstract: 7501. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
Sources/Disclosures

Collapse
Source:

Healio Interviews

Disclosures: Cohen reports serving as a consultant for AstraZeneca, Bristol Myers Squibb, Genentech/Roche, GSK, Ichnos, iTeos, Janssen, Pfizer and Sanofi; receiving funding from Genentech/Roche, GSK, Janssen and Novartis; and having patents with Novartis.

Read more about

multiple myeloma
isatuximab-irfc
 

Related Content